UNSPSC 51351512: Nomegestrol

This classification denotes a therapeutic progestin with the molecular formula C21H28O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10F89177CO, chemically known as 19-norpregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl- but generally known as nomegestrol, which bears US NIH Compound Identifier 68783. European Medicines Agency schedules Nomegestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09345MIG.

UNSPSC 51351512 Nomegestrol is a Commodity code under which state and local governments procure generic pharmaceutical products and over-the-counter medications through cooperative purchasing vehicles and direct manufacturer contracts. The scope of work encompasses supplying finished pharmaceutical products with specific National Drug Codes (NDC), SKUs, and packaging configurations to authorized wholesalers serving state agencies, counties, municipalities, and other public health facilities. Products must meet current Good Manufacturing Practices (cGMP) certification and comply with FDA requirements and the Drug Supply Chain Security Act (DSCSA), with expiration dates guaranteeing at least one year from manufacture and a minimum six-month shelf life. Vendors typically establish relationships with two or more authorized wholesalers maintaining chargeback systems and offer flexible pricing structures including flat price, net price formats (NF30, NF60, NF90), or WAC-minus arrangements.

Cooperative purchasing alliances dominate the issuing body mix for this code. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota and Oregon. The MMCAP RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendors effective July 1, 2026 on a two-year initial term. Evaluation prioritizes price competitiveness (75 percent) alongside compliance with administrative fee data format requirements, EDI capability, and agreement to a 3 percent administrative fee. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000. No specific dollar value or set-aside designation was disclosed in the solicitation.